Comments on: Keeping Biogen Idec Innovative: Jim Mullen Interview (Part 2)

By: VentureBeat » Weekend update: The spinning of Baby Einstein, multiple-med confusion, and more

Tue, 21 Aug 2007 15:01:50 +0000

[...] — In a lengthy interview with Robert Buderi of Xconomy.com (part one is here, part two is here), Biogen Idec CEO Jim Mullen waxes philosophical on what he sees as a coming era of rapid [...]

By: JOE PO

JOE PO — Sun, 19 Aug 2007 13:05:54 +0000

I MET JIM MULLEN AT THE ANNUAL SHAREHOLDERS MEETING, AND WAS SURPRISED HE SAT WITH ME FOR THE LUNCH (THE ONLY GUY WITH A CANE IN THE ROOM). AS A FORMER SENIOR OFFICER OF SEVERAL LARGE COMPANIES, I WAS VERY IMPRESSED WITH HIS DEPTH OF KNOWLEDGE OF MS, BUSINESS ACUMEN AND HIS PATIENT CENTERED THINKING. MOREOVER, HIS SELECTION OF NEW TOP TALENT WAS EQUALLY IMPRESSIVE. HIS DOWN TO EARTH AND APPROACHABLE DEMEANOR IS DISARMING WITH ALMOST A HUMBLE CONFIDENCE. AS ONE WITH MS, MY INTERESTS WERE MAINLY IN THEIR MS FRANCHISE, AND I WAS SURPRISED BY THE PIPELINE’S BREADTH THAT YOU NOTED IN YOUR ARTICLE. BIIB HAS A LOT OF UNTAPPED VALUE.

By: YolkiePolkie

YolkiePolkie — Sat, 18 Aug 2007 10:34:33 +0000

Good call and if so, will he insist they leave them alone like he did with Syntonix or would he be happy to be integrated… As Amgen has its woes and Genentech is owned by Roche, BIIB has to be the number one biotech aquisition target for big pharma who seriously want to get into biotech. Hmmm – from what I hear all the big ones do…

By: robert crites

robert crites — Fri, 17 Aug 2007 18:02:02 +0000

Great interview…what about a big pharma buying out BIIB? Is this a real possibility that Mr. Mullen and his team are dealing with?